Vetter Development Services USA, Inc.

Primary objective: To evaluate the efficacy of different doses of lunsekimig (SAR443765) compared with placebo in adult subjects with moderate to severe uncontrolled asthma.

To investigate the transthyretin-lowering effect and long-term safety of eplontersen in Chinese subjects with inherited or wild-type transthyretin amyloid cardiomyopathy

The relative change from baseline in uPCR was compared after 9 months of subcutaneous administration of sibeprenlimab or placebo added to standard of care.